Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat with Radiation and 5-FU in Pancreatic Cancer
NCT00948688Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2009
- Primary completion
- Jun 2012
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in pancreatic adenocarcinoma (PDAC), sponsored by Massachusetts General Hospital. Started Aug 2009; status: terminated.
02
Drugs
vorinostat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00948688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00948688.